 "Biocon UAE venture partners with Novartis to launch diabetes drugs")
NeoBiocon - a collaboration between Biocon Ltd and Dr B R Shetty (chairman of the UAE-based Neopharma) - has partnered with Novartis Middle East FZE, to market Jalra (vildagliptin) and Jalra-M (combination of vildagliptin and metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.
Vildagliptin is an oral anti-diabetic agent that delivers consistent and robust blood sugar control in patients with type 2 diabetes. It is a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, which does not cause weight gain and have low risks for hypoglycaemia.
The overall market for oral hypoglycaemic agents (OHA) in UAE is estimated to be $ 115 million and DPP-IV inhibitors command nearly 50 percent share of this market. A novel product, Vildagliptin is available both as monotherapy as well as in combination with metformin. Together vildagliptin and vildagliptin-metformin combination drug commands over 30 percent of the DPP-IV market in UAE.
Jalra-M in the country and the launch is scheduled for January 2016. These products will be manufactured by Novartis in Europe and marketed and distributed by NeoBiocon in UAE after local release through Neopharma.
Dr Kiran Mazumdar-Shaw, CMD, Biocon, said, “Biocon is committed to offer advanced therapies for diabetics the world over. We are indeed pleased to partner with Novartis to offer Jalra and Jalra-M to address the growing needs of type 2 diabetes patients in UAE.”
The partnership between NeoBiocon and Novartis will benefit the large and increasing number of diabetics in the UAE. This will result in enhancing access to this novel oral hypoglycaemic agent by leveraging the huge marketing network of NeoBiocon & distribution network of NMC Healthcare. Novartis will continue to market its brands Galvus & Galvusmet in the UAE.
NeoBiocon is amongst the fastest growing pharmaceutical companies in UAE and is ranked among the top 25 pharma companies in the region. It is the leading generic pharma company in UAE in the cardiovascular segment with successful brands like Statix (atorvastatin).
Established in 2011, NeoBiocon markets its own brands in UAE & other GCC markets in various therapies such as metabolics, oncology, asthma & allergic rhinitis, anti-infectives and others. Through this partnership with a multinational pharma company, NeoBiocon has further strengthened its resolve to create a positive impact in the lives of the patients through innovative products.
Vildagliptin is an oral anti-diabetic agent that delivers consistent and robust blood sugar control in patients with type 2 diabetes. It is a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, which does not cause weight gain and have low risks for hypoglycaemia.
The overall market for oral hypoglycaemic agents (OHA) in UAE is estimated to be $ 115 million and DPP-IV inhibitors command nearly 50 percent share of this market. A novel product, Vildagliptin is available both as monotherapy as well as in combination with metformin. Together vildagliptin and vildagliptin-metformin combination drug commands over 30 percent of the DPP-IV market in UAE.
More From This Section
NeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and
Jalra-M in the country and the launch is scheduled for January 2016. These products will be manufactured by Novartis in Europe and marketed and distributed by NeoBiocon in UAE after local release through Neopharma.
Dr Kiran Mazumdar-Shaw, CMD, Biocon, said, “Biocon is committed to offer advanced therapies for diabetics the world over. We are indeed pleased to partner with Novartis to offer Jalra and Jalra-M to address the growing needs of type 2 diabetes patients in UAE.”
The partnership between NeoBiocon and Novartis will benefit the large and increasing number of diabetics in the UAE. This will result in enhancing access to this novel oral hypoglycaemic agent by leveraging the huge marketing network of NeoBiocon & distribution network of NMC Healthcare. Novartis will continue to market its brands Galvus & Galvusmet in the UAE.
NeoBiocon is amongst the fastest growing pharmaceutical companies in UAE and is ranked among the top 25 pharma companies in the region. It is the leading generic pharma company in UAE in the cardiovascular segment with successful brands like Statix (atorvastatin).
Established in 2011, NeoBiocon markets its own brands in UAE & other GCC markets in various therapies such as metabolics, oncology, asthma & allergic rhinitis, anti-infectives and others. Through this partnership with a multinational pharma company, NeoBiocon has further strengthened its resolve to create a positive impact in the lives of the patients through innovative products.